TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer
Brief Summary: To select a better agent between S-1 or gemcitabine in combination with cisplatin for the conventional chemotherapy platform for future development in advanced Biliary Tract Adenocarcinoma (BTA), the investigators conduct a randomized phase II trial of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first line therapy in advanced BTA.


Options:
A: Arm Label: Gemcitabine/Oxaliplatin with Erlotinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva) | Arm Label: Gemcitabine/Oxaliplatin without Erlotinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine/Oxaliplatin | Intervention Type: DRUG; Name: Gemcitabine/Oxaliplatin; Assigned to Arm(s): Gemcitabine/Oxaliplatin without Erlotinib | Intervention Type: DRUG; Name: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva); Assigned to Arm(s): Gemcitabine/Oxaliplatin with Erlotinib
B: Arm Label: SP treatment; Type: EXPERIMENTAL; Interventions: Drug: S-1 plus cisplatin | Arm Label: GP treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: S-1 plus cisplatin; Assigned to Arm(s): SP treatment | Intervention Type: DRUG; Name: Gemcitabine plus Cisplatin; Assigned to Arm(s): GP treatment
C: Arm Label: Arm A- p-Gemox; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab plus GEMOX chemotherapy, Drug: GEMOX chemotherapy | Arm Label: Arm B-GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: GEMOX chemotherapy | Intervention Type: DRUG; Name: Panitumumab plus GEMOX chemotherapy; Assigned to Arm(s): Arm A- p-Gemox | Intervention Type: DRUG; Name: GEMOX chemotherapy; Assigned to Arm(s): Arm A- p-Gemox, Arm B-GEMOX
D: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.
Brief Summary: NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.


Options:
A: Intervention Type: DRUG; Name: MK0869, aprepitant / Duration of Treatment: 3 days; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron / Duration of Treatment: 4 days; Assigned to Arm(s): N/A
B: Arm Label: Placebo + Granisetron + Dexamethasone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Granisetron, Drug: Dexamethasone, Drug: Placebo | Arm Label: Rolapitant; Type: EXPERIMENTAL; Interventions: Drug: Rolapitant, Drug: Granisetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Rolapitant; Assigned to Arm(s): Rolapitant | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone
C: Intervention Type: DRUG; Name: Palonosetron; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): N/A
D: Arm Label: Netupitant and Palonosetron plus dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Netupitant and Palonosetron, Drug: Dexamethasone | Arm Label: Aprepitant and Palonosetron plus dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aprepitant, Drug: Palonosetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Netupitant and Palonosetron; Assigned to Arm(s): Netupitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Palonosetron; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone, Netupitant and Palonosetron plus dexamethasone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability and Effectiveness of Household Water Chlorination in Reducing the Prevalence of Diarrhea Among Under Five Children in Eastern Ethiopia
Brief Summary: The Millenium development goals (MDGs) call for reducing by half the proportion of people without sustainable access to safe drinking water. This goal was adopted in large part because safe drinking water has been seen as critical to fighting diarrheal disease. Source protection is considered the main intervention area to achieve this goal. However, research worldwide that has shown that even drinking water which is safe at the source is subject to frequent and extensive fecal contamination during collection, storage and use in the home. This contamination is through the introduction of cups, dippers or hands, contamination by flies, cockroaches, and rats. Even piped water supplies of adequate microbial quality can pose infectious disease risks if they become contaminated due to unsanitary collection, storage conditions and practices within households.

To reduce this problem, point-of-use water treatment has been advocated as a means to substantially decrease the global burden of diarrhea and to contribute to the MDGs. However, research indicates that there are many unanswered questions around Household water treatment (HWT) that require small or medium scale epidemiological studies and randomized controlled trials, especially with regard to effectiveness, acceptability and identifying suitable target populations. Some of the most urgent questions to be resolved are:(1) How much of the currently cited disease reduction of HWT is due to bias? (2) What is the effect of HWT on nutritional status (weight gain and growth)?(3) At which populations should HWT be targeted? (4) Is it acceptable and sustainable in poor communities where the risk of diarrheal disease is high.

hypothesis: Do household water treatment with chlorine reduce diarrhea among underfive children? hypothesis: Do household water treatment with chlorine acceptable in the community?


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Solar Water Disinfection (SODIS) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Solar Water Disinfection (SODIS); Assigned to Arm(s): 1
B: Arm Label: SODIS Bottles given; Type: ACTIVE_COMPARATOR; Interventions: Other: SODIS Bottle | Arm Label: Usual practices; Type: ACTIVE_COMPARATOR; Interventions: Other: SODIS Bottle | Intervention Type: OTHER; Name: SODIS Bottle; Assigned to Arm(s): SODIS Bottles given, Usual practices
C: Arm Label: Household water treatment; Type: EXPERIMENTAL; Interventions: Other: household water treatment | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: household water treatment; Assigned to Arm(s): Household water treatment
D: Intervention Type: DRUG; Name: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding for 6 months postpartum; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Investigator-initiated, Randomized, Open-label Single-center Study of the Effect of Denosumab on the Prevention of Bone Mineral Density Loss After Renal Transplantation
Brief Summary: The primary objective of the study is to examine the effect of denosumab on lumbar spine bone mineral density (BMD) after one year of treatment in newly transplanted renal allograft recipients. Secondary endpoints include BMD changes at the total hip and the femoral neck, changes in body height, changes in bone mineral metabolism parameters, incidence of fractures, and allograft function at one year. Safety measurements include the occurrence of rejection episodes, infectious complications, graft loss and mortality.

* Trial with medicinal product


Options:
A: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab (Prolia) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Denosumab (Prolia); Assigned to Arm(s): Denosumab
B: Arm Label: Cholecalciferol 100 000 UI; Type: EXPERIMENTAL; Interventions: Drug: Cholecalciferol 100 000 UI | Arm Label: Cholecalciferol 12 000 UI (Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol 12 000 UI | Intervention Type: DRUG; Name: Cholecalciferol 100 000 UI; Assigned to Arm(s): Cholecalciferol 100 000 UI | Intervention Type: DRUG; Name: Cholecalciferol 12 000 UI; Assigned to Arm(s): Cholecalciferol 12 000 UI (Control)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Postassium citrate; Type: EXPERIMENTAL; Interventions: Drug: Potassium citrate | Arm Label: Potassium chloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Potassium chloride | Intervention Type: DRUG; Name: Potassium citrate; Assigned to Arm(s): Postassium citrate | Intervention Type: DRUG; Name: Potassium chloride; Assigned to Arm(s): Potassium chloride

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam
Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in infants in Vietnam. In addition, we evaluate different dosages and schedules to determine the best regimen to test in a clinical trial.


Options:
A: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
B: Intervention Type: BIOLOGICAL; Name: Live attenuated rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
D: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam
Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in infants in Vietnam. In addition, we evaluate different dosages and schedules to determine the best regimen to test in a clinical trial.


Options:
A: Arm Label: rotavirus vaccine 116E 1 X 10(4); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Arm Label: rotavirus vaccine 116E 1 X 10(5); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Intervention Type: BIOLOGICAL; Name: Oral Rotavirus Vaccine 116E Live Attenuated; Assigned to Arm(s): rotavirus vaccine 116E 1 X 10(4), rotavirus vaccine 116E 1 X 10(5)
B: Arm Label: Group 1 - BRV-PV Lot A; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot A + DPT-HepB-Hib + OPV | Arm Label: Group 2 - BRV-PV Lot B; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot B + DPT-HepB-Hib + OPV | Arm Label: Group 3 - BRV-PV Lot C; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot C + DPT-HepB-Hib + OPV | Arm Label: Group 4 - ROTARIX; Type: ACTIVE_COMPARATOR; Interventions: Biological: ROTARIX + DPT-HepB-Hib + OPV | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot A + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 1 - BRV-PV Lot A | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot B + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 2 - BRV-PV Lot B | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot C + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 3 - BRV-PV Lot C | Intervention Type: BIOLOGICAL; Name: ROTARIX + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 4 - ROTARIX
C: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration
D: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam
Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in infants in Vietnam. In addition, we evaluate different dosages and schedules to determine the best regimen to test in a clinical trial.


Options:
A: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1
C: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alcohol and Atherosclerosis Pilot Study
Brief Summary: We propose a pilot study to determine the feasibility of a long-term clinical trial of alcohol intake on atherosclerosis, the first step in determining whether moderate drinking prevents cardiovascular disease and hence in understanding the full health effects of alcohol across the population. We will randomize 40 participants aged 55 and older to a six-month period of consumption of 1 glass per day of either pure alcohol (diluted to the strength of wine) or water. At baseline and after 6 months, we will measure several standard and novel cardiovascular risk markers in the blood and will perform magnetic resonance imaging to measure atherosclerosis of the aorta.


Options:
A: Arm Label: Luxembourg diet + wine; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Arm Label: conventional + wine; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: conventional; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: Luxembourg diet; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional diet +/- wine; Assigned to Arm(s): conventional, conventional + wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Luxembourg variant of Mediterranean diet + physical activity +/- wine; Assigned to Arm(s): Luxembourg diet, Luxembourg diet + wine
B: Arm Label: Glass; Type: ACTIVE_COMPARATOR; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Arm Label: Can 1; Type: EXPERIMENTAL; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Arm Label: Can 2; Type: EXPERIMENTAL; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Intervention Type: OTHER; Name: Can 1; Assigned to Arm(s): Can 1, Can 2, Glass | Intervention Type: OTHER; Name: Can 2; Assigned to Arm(s): Can 1, Can 2, Glass | Intervention Type: OTHER; Name: Glass; Assigned to Arm(s): Can 1, Can 2, Glass
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Ethanol-free beverage | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: ethanol | Intervention Type: OTHER; Name: ethanol; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Ethanol-free beverage; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: alcohol; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Children with cerebral palsy (CP) undergo multiple painful procedures such as Botulinum toxin (BTX) injections that are administered several times a year. While clown care reduces preoperative anxiety, its effect on painful procedures has not been assessed. We hypothesized that medical clowning reduces pain and anxiety during BTX injections.


Options:
A: Arm Label: humanoid robot distration; Type: N/A; Interventions: N/A | Arm Label: control; Type: N/A; Interventions: N/A
B: Arm Label: Standard intervention; Type: SHAM_COMPARATOR; Interventions: Other: standard | Arm Label: clown care; Type: EXPERIMENTAL; Interventions: Behavioral: clown care | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): Standard intervention | Intervention Type: BEHAVIORAL; Name: clown care; Assigned to Arm(s): clown care
C: Arm Label: music; Type: EXPERIMENTAL; Interventions: Behavioral: music | Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: music | Intervention Type: BEHAVIORAL; Name: music; Assigned to Arm(s): Standard care, music
D: Arm Label: Standard technique; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard technique | Arm Label: Parent participation technique; Type: EXPERIMENTAL; Interventions: Behavioral: Parent participation technique | Intervention Type: BEHAVIORAL; Name: Standard technique; Assigned to Arm(s): Standard technique | Intervention Type: BEHAVIORAL; Name: Parent participation technique; Assigned to Arm(s): Parent participation technique

Answer: B